Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RUBIUS THERAPEUTICS, INC.

(RUBY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer

08/30/2021 | 08:01am EDT

CAMBRIDGE Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Jim Jogerst as chief business officer. He will oversee business development strategy and execution, including strategic partnerships, collaborations and alliances that align with Rubius’ overall corporate strategy.

“Jim brings more than 20 years of experience in mergers and acquisitions, business development and licensing transactions, valued in excess of $20 billion,” said Pablo J. Cagnoni, M.D., president and chief executive officer at Rubius Therapeutics. “As we continue to grow our promising pipeline of Red Cell Therapeutics, Jim’s expertise and strong track record of success with biotech and pharmaceutical deals will be critical in identifying partnerships to help us reach as many patients as possible across the globe.” 

Jim joins Rubius from Janssen Pharmaceuticals, where he led licensing transactions in the company’s Infectious Diseases and Vaccines business. Before that, Mr. Jogerst spent nearly ten years at Alcon, Inc., where he developed and executed business development and licensing and mergers and acquisitions strategy for Alcon’s three global franchises: surgical, pharmaceutical and vision care. Earlier in his career Mr. Jogerst held executive positions in several investment banking firms in Dallas after starting his career in consulting with Arthur Andersen.

“Red Cell Therapeutics have the potential to transform how cancer and autoimmune diseases are treated,” said Jim Jogerst, chief business officer at Rubius Therapeutics. “I am thrilled to join this industry-leading team at such an exciting moment in the company’s trajectory and look forward to applying my business development and partnership expertise to identify the right partners to help deliver on the promise of Rubius’ RED PLATFORM®.”

Mr. Jogerst has an MBA in Finance and International Business from Pepperdine University and a BA in Economics and Political Science from the University of North Texas. He also holds the Chartered Financial Analyst (“CFA”) designation.

About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was named among the 2020 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2021 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding our expectations with respect to the therapeutic potential of our pipeline of Red Cell Therapeutics and our expectations regarding our strategy, business plans, leadership and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the development of our Red Cell Therapeutic product candidates and their therapeutic potential and other risks identified in our filings with the U.S. Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

Contacts:

Investors
Elhan Webb, CFA, Vice President of Investor Relations
elhan.webb@rubiustx.com 

Media
Marissa Hanify, Director, Corporate Communications
Marissa.hanify@rubiustx.com 

Dan Budwick, 1AB
+1 (973) 271-6085
dan@1abmedia.com 


Primary Logo


© GlobeNewswire 2021
All news about RUBIUS THERAPEUTICS, INC.
10/19RUBIUS THERAPEUTICS : Morgan Stanley Adjusts Rubius Therapeutics' Price Target to $22 from..
MT
10/04RUBIUS THERAPEUTICS : Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory..
AQ
10/01RUBIUS THERAPEUTICS : Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory..
GL
10/01Rubius Therapeutics Announces Preclinical Data for RTX-224, a Broad Immune Costimulator..
CI
09/01Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare ..
GL
08/30Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer
GL
08/30Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer
CI
08/20RUBIUS THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
08/10RUBIUS THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Provides Business ..
AQ
08/09RUBIUS THERAPEUTICS' : Q2 Net Loss Widens
MT
More news
Analyst Recommendations on RUBIUS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -197 M - -
Net cash 2021 98,4 M - -
P/E ratio 2021 -7,25x
Yield 2021 -
Capitalization 1 456 M 1 456 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 248
Free-Float 93,3%
Chart RUBIUS THERAPEUTICS, INC.
Duration : Period :
Rubius Therapeutics, Inc. Technical Analysis Chart | RUBY | US78116T1034 | MarketScreener
Technical analysis trends RUBIUS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 16,22 $
Average target price 29,67 $
Spread / Average Target 82,9%
EPS Revisions
Managers and Directors
Pablo J. Cagnoni President, Chief Executive Officer & Director
Jose Carmona Treasurer, Chief Financial & Accounting Officer
David R. Epstein Executive Chairman
Spencer Fisk Senior Vice President-Technical Operations
Christina Coughlin Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
RUBIUS THERAPEUTICS, INC.113.70%1 456
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610